Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Thrombomodulin alfa - Asahi Kasei Pharma Corp

Next Previous
Drug Profile

Thrombomodulin alfa - Asahi Kasei Pharma Corp

Alternative Names: ART-123; AT 908; Human recombinant thrombomodulin - Asahi Kasei Pharma Corp; Recombinant human soluble thrombomodulin - Asahi Kasei Pharma Corp; Recombinant thrombomodulin alfa - Asahi Kasei Pharma Corp; Recombinant thrombomodulin alpha - Asahi Kasei Pharma Corp; Recomodulin; Recomodulin® anticoagulant intravenous infusion 12800; rhs-TM - Asahi Kasei Pharma Corp; Thrombomodulin alpha - Asahi Kasei Pharma Corp; TMD-123

Latest Information Update: 22 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Asahi Kasei; Asahi Kasei Pharma Corp
  • Developer Asahi Kasei; Asahi Kasei Pharma America Corp; Asahi Kasei Pharma Corp; Veloxis Pharmaceuticals
  • Class Anti-inflammatories; Anticoagulants; Antifibrotics; Antithrombotics; Peptides; Platelet membrane glycoproteins; Recombinant proteins
  • Mechanism of Action Protein C stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Disseminated intravascular coagulation
  • Phase III Peripheral neuropathies
  • Discontinued Deep vein thrombosis; Idiopathic pulmonary fibrosis

Most Recent Events

  • 10 Jan 2026 Adverse event and pharmacokinetics data from the Phase-I clinical trials in Peripheral neuropathies presented at the 2026 Gastrointestinal Cancers Symposium (ASCO-GI-2026)
  • 02 Jul 2025 Phase-III clinical trials in Peripheral nervous system diseases (Chemotherapy-induced) in Japan (IV)
  • 11 Dec 2024 Thrombomodulin alfa is still in phase III trials for Disseminated intravascular coagulation in Brazil, United Kingdom, Australia, Croatia (https://www.asahi-kasei.co.jp/pharma/en/research_development/pipeline/)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top